Samsung Bioepis receives positive evaluations for ‘Flixabi’ from CHMP

Published: 2016-04-06 14:11:18

Updated: 2016-04-06 14:11:18

On the 2^nd, Samsung Bioepis announced it received positive opinions from the European Medicines Agency(EMA) and the Committee for Medicinal Products for Human Use(CHMP) for its autoimmune disease treatment Flixabi.

Flixabi, a biosimilar of Remicade(infliximab) that is similar to Lenflexis approved from the Korean Ministry of Food and Drug Safety last December, was applied by Samsung Bioepis un...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.

Samsung Bioepis receives positive evaluations for ‘Flixabi’ from CHMP

On the 2nd, Samsung Bioepis announced it received positive opinions from the European Medicines Agency(EMA) and the Committee for Medicinal Products for Human Use(CHMP) for its autoimmune disease treatment Flixabi.

Fees

On the 2^nd, Samsung Bioepis announced it received positive opinions from the European Medicines Agency(EMA) and the Committee for Medicinal Products for Human Use(CHMP) for its autoimmune disease treatment Flixabi.